Web Analytics

3 Latest Announced Rounds

$2,265.93M Raised in 95 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Vicebio

start up
United Kingdom - Londres, Angleterre, Royaume-Uni
  • 24/09/2024
  • Series B
  • $100,000,000

Vicebio uses the molecular clamp technology to develop innovative vaccines against life-threatening respiratory viruses. The Molecular Clamp technology provide unique stabilisation of viral envelop glycoproteins making possible highly effective, ready-to-use, and multivalent single shot respiratory virus vaccines.


Related People

Emmanuel HanonFounder

Emmanuel Hanon Belgium - Brussels Metropolitan Area

Research & Development leader, C-level Executive, with more than 20 years experience at GSK, last 7 years running the global vaccines RD for GSK. Led the discovery and development of five major Vaccines : Quadrivalent Influenza (Fluarix and Flulaval Quadrivalent), Shingles (Shingrix), Malaria (Mosquirix), RSV older adult, and MenABCWY 5-in-1 Vaccines.

Broad functional leadership experience includes R&D, medical, clinical, regulatory, technical CMC, manufacturing and quality operations. Expert in Immunology, Microbiology, and Vaccinology